Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798669 | 0.78 | AHR (0.33) | NAMPTKDM4ENPC1RAB9AAHR | |
| SCHEMBL18626423 | 0.77 | HAVCR2 (0.39) | NAMPTCYP1A2KDM4EAHR | |
| SCHEMBL23761312 | 0.77 | PIK3CG (0.45) | CYP1A2KDM4ENPC1PKMKLF5 | |
| SCHEMBL9108919 | 0.77 | PIK3CG (0.35) | NAMPTKDM4ENPC1MAPTRAB9A | |
| SCHEMBL9109466 | 0.77 | AHR (0.53) | NAMPTAHR | |
| SCHEMBL26008734 | 0.75 | PIK3CG (0.30) | — | |
| SCHEMBL25825583 | 0.74 | PDE10A (0.32) | NAMPTAHR | |
| SCHEMBL25848350 | 0.71 | NAMPT (0.30) | NAMPT | |
| SCHEMBL6900236 | 0.70 | JAK2 (0.46) | NAMPTCYP1A2KDM4ENPC1 | |
| SCHEMBL24782813 | 0.68 | KDM4E (0.47) | CYP1A2CYP2A6KDM4ENPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | NAMPT 1361/4885CYP1A2 3528/4885CYP2A6 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.